

Methods for adjusting for treatment switches in late-stage cancer trials

A workshop funded by the MRC Network of Hubs for Trials Methodology Research.

Lead organiser: Ian White, MRC Biostatistics Unit, Cambridge

Location: MRC Head office, 14th Floor, One Kemble Street, London WC2B 4AN

Date: 20th February 2012

Nearest Tubes: Covent Garden, Holborn and Temple underground stations.

Morning: Methods. Chair: Paula Williamson (North West HTMR)			
10:00	Ian White	Cambridge HTMR	Methods for handling treatment switching: rank-preserving structural nested failure time models, inverse-probability-of-censoring weighting, and marginal structural models
10:45	Susie Dodd	North West HTMR	Departure from treatment protocol in published RCTs: a review
11:00	Tea / coffee		
11:20	James Morden	Institute of Cancer Research	Methods for adjusting survival estimates in the presence of treatment crossover - Simulation studies
	Nick Latimer	University of Sheffield	
12:05	Neil Hawkins	ICON PLC & University of Glasgow	Methods for health economic models in metastatic cancer
12:50	Lunch		
Afternoon: Perspectives. Chair: Ian White			
13:50	Xin Huang	Pfizer & PSI	Adjusting the Crossover Effect in Survival Analysis Using a Rank Preserving Structural Failure Time Model: The Case of Sunitinib GIST Trial
14:35	Rob Hemmings	Medicines and Healthcare products Regulatory Agency	Treatment switches in cancer trials - problems, pitfalls and (no) solutions
15:20	Tea / coffee		
15:40	Martin Pitt & Martin Hoyle	Peninsula Technology Assessment Group	Dealing with treatment switches in cost-effectiveness analysis: the NICE experience
16:10	Claire Watkins	AstraZeneca	Discussants & general discussion
	Chris Metcalfe	Bristol HTMR	
17:00	End		